PT  - JOURNAL ARTICLE
AU  - KRIEGER-HINCK, NINA
AU  - GUSTKE, HEIKE
AU  - VALENTINER, URSULA
AU  - MIKECZ, PAL
AU  - BUCHERT, RALPH
AU  - MESTER, JANOS
AU  - SCHUMACHER, UDO
TI  - Visualisation of Neuroblastoma Growth in a <em>Scid</em> Mouse Model Using [<sup>18</sup>F]FDG and [<sup>18</sup>F]FLT-PET
DP  - 2006 Sep 01
TA  - Anticancer Research
PG  - 3467--3472
VI  - 26
IP  - 5A
4099  - http://ar.iiarjournals.org/content/26/5A/3467.short
4100  - http://ar.iiarjournals.org/content/26/5A/3467.full
SO  - Anticancer Res2006 Sep 01; 26
AB  - Background: Tumor therapy has been monitored using the metabolic indicator [18F]fluorodeoxyglucose ([18F]FDG). However, the nucleotide precursor [18F]fluoro-thymidine ([18F]FLT) is in principle more specific as it is incorporated into DNA. Thus, the [18F]FDG and [18F]FLT uptake by human neuroblastomas grown in Scid mice are compared in this study. Materials and Methods: Scid mice were inoculated with human neuroblastoma cells. Tumor imaging was performed with a human whole-body full-ring PET scanner. Furthermore, the tumor weight and the cell proliferation rate were determined. Results: Neuroblastomas could be visualised using [18F]FDG in 40% and with [18F]FLT in 70% of the cases. [18F]FDG or [18F]FLT uptake could not be visualised in neuroblastomas less than 1.0 g in weight. No correlation between the cell proliferation rate and tracer uptake could be detected. Conclusion: [18F]FLT showed a higher uptake than [18F]FDG and, therefore, might be more suitable for monitoring anticancer therapy, at least in this tumor model. Copyright© 2006 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved